Debiopharm picks up a bargain-basement Wee1 companion
Given how disappointing Repare's PKMYT1 inhibitor lunresertib has turned out to be, the $10m up front the company got from Debiopharm for it on Tuesday is probably a fair reflection of the asset's value. Repare, which earlier lost Roche as a partner for the ATR inhibitor camonsertib, put lunresertib up for licensing last year, turning its focus to the earlier-stage projects RP-1664 (PLK4 inhibitor) and RP-3467 (DNA Pol θ). But for Debiopharm this could be a canny move. For a sum that won't break the bank the private Swiss firm has gained a molecule it can combine with its Almac Discovery-originated Wee1 inhibitor Debio 0123. After all, it's as monotherapy where lunresertib has disappointed, and the remaining hope for PKMYT1 inhibition is as part of a combo with Wee1. Two companies, Schrödinger and Acrivon, are advancing molecules that hit both targets, and expect to report their first clinical results this year. Lunresertib has human data as part of a camonsertib doublet, but backing for a Debio 0123 combo has so far only been preclinical, with an AACR poster claiming synergistic activity in in vivo models of ovarian and breast cancers.
Clinical approaches combining PKMYT1 and Wee1 inhibition
| Project | Company | Mechanism | Status | Note |
|---|---|---|---|---|
| ACR-2316 | Acrivon Therapeutics | PKMYT1/ Wee1 inhibitor | Ph1 ACR-2316-101 in solid tumours | At dose level 4; data due H2 2025 |
| SGR-3515 | Schrödinger | PKMYT1/ Wee1 inhibitor | Ph1 SGR-3515-101 in solid tumours | Data due H2 2025 |
| Lunresertib + Debio 0123 | Repare/ Debiopharm | PKMYT1 inhibitor + Wee1 inhibitor | Ph1 Mythic, monoRx + combos | Lunresertib disappointed as monoRx; combo data only with camonsertib; Debio 0123 combo had preclinical poster at AACR 2025 |
Source: OncologyPipeline.
66
